Status:
COMPLETED
Cannabidiol and Focus Study (CBD-Focus)
Lead Sponsor:
University of Northern Colorado
Conditions:
Healthy
Eligibility:
All Genders
18-50 years
Phase:
NA
Brief Summary
Cannabidiol (CBD), a non-psychoactive hemp derivative, is an attractive therapeutic target, and is most supported by the scientific community as an antiepileptic, anxiolytic, and antipsychotic. Additi...
Detailed Description
BACKGROUND: Cannabidiol (CBD), a non-psychoactive hemp derivative, is an attractive therapeutic target, and is most supported by the scientific community as an antiepileptic, anxiolytic, and antipsych...
Eligibility Criteria
Inclusion
- Currently completing at least 150 minutes of moderate to vigorous physical activity per week
- Have a body mass index under 29.9
- No significant physical or mental health (without the presence of chronic depression or anxiety) conditions
- No presence or past diagnosis of eating disorders
Exclusion
- Subjects may not have an allergy to soy.
- All study subjects must also be free of cannabis product use or regular high doses of antioxidants for the previous 8 weeks.
- Participants receive a $200 Visa Gift Card after the last study visit is completed.
Key Trial Info
Start Date :
January 10 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05189275
Start Date
January 10 2022
End Date
December 31 2022
Last Update
September 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Of Northern Colorado
Greeley, Colorado, United States, 80639